ConductScience.org, home

Paper42017407

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.

Joshi S and 7 others. Headache, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study. Papers, record 42017407. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42017407

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.
PubMed
Journal
Headache
PubMed
Year
2026
PubMed
Publication types
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Joshi SShivang
2Tassorelli CCristinahttps://orcid.org/0000-0003-1513-2113
3Matharu MManjit
4Alsaadi TTaoufikhttps://orcid.org/0000-0002-7513-5706
5Vallarino CCarlos
6Viktrup LLars
7Vincent MMaurice
8Robinson RLRebecca Lhttps://orcid.org/0000-0003-1490-0491

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Migraine DisordersMajor topic
Antibodies, Monoclonal, HumanizedMajor topic
TopiramateMajor topic
AmitriptylineMajor topic
Humans
Treatment Outcome
Female
Male
Adult
Administration, Oral
Middle Aged

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Eli Lilly and CompanyPubMed

Source PubMed

Download CSV of grants

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133267788Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019.J Headache Pain2020https://conductscience.org/library/papers/33267788PubMed
242017407Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.Headache2026https://conductscience.org/library/papers/42017407PubMed
314152626TREATMENT OF CHRONIC TENSION HEADACHE.Lancet1964https://conductscience.org/library/papers/14152626PubMed
422671714The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines.Headache2012https://conductscience.org/library/papers/22671714PubMed
541224245Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).Pharmacoepidemiol Drug Saf2025https://conductscience.org/library/papers/41224245PubMed
630536394The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.Headache2019https://conductscience.org/library/papers/30536394PubMed
729813147Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.JAMA Neurol2018https://conductscience.org/library/papers/29813147PubMed
834743579Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.Cephalalgia2022https://conductscience.org/library/papers/34743579PubMed
932209650Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.Neurology2020https://conductscience.org/library/papers/32209650PubMed
1037792218Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE.Neurol Ther2023https://conductscience.org/library/papers/37792218PubMed
1132183872Adverse drug reactions associated with amitriptyline - protocol for a systematic multiple-indication review and meta-analysis.Syst Rev2020https://conductscience.org/library/papers/32183872PubMed
1222683887Canadian Headache Society guideline for migraine prophylaxis.Can J Neurol Sci2012https://conductscience.org/library/papers/22683887PubMed
1332722936Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults.Cephalalgia2020https://conductscience.org/library/papers/32722936PubMed
1435410119The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates.J Headache Pain2022https://conductscience.org/library/papers/35410119PubMed
1529368949Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.Cephalalgia2018https://conductscience.org/library/papers/29368949PubMed
1631563224Migraine: Epidemiology, Burden, and Comorbidity.Neurol Clin2019https://conductscience.org/library/papers/31563224PubMed
1735690723European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.J Headache Pain2022https://conductscience.org/library/papers/35690723PubMed
1834145431Diagnosis and management of migraine in ten steps.Nat Rev Neurol2021https://conductscience.org/library/papers/34145431PubMed
1941017292Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study.Headache2026https://conductscience.org/library/papers/41017292PubMed
2035687795Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.Brain Behav2022https://conductscience.org/library/papers/35687795PubMed

See all 35 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42017407Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.Headache2026https://conductscience.org/library/papers/42017407

Source PubMed

Download CSV of cited by

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
EudraCTEUPAS33068

Source PubMed

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42017407

GET https://conductscience.org/api/papers/v1/42017407/references?page=2